Document is current
Any future updates will be listed below
-
Authors
Lamy, Constance
Laurent, Léonard
Choussy, Olivier
Pouget, Nicolas
Lecuru, Fabrice
Reyal, Fabien
Plissonnier, Anne-Sophie
Kadi, Amir
Berger, Frédérique
Martin, Joey
Dubray-Vautrin, Antoine
Marret, Grégoire
Borcoman, Edith
Romano, Emanuela
Sablin, Marie-Paule
Cabel, Luc
Pasquesoone, Camille
Lantz, Olivier
Louis, Delphine
Gorret, Doriane
Da Silva, Ines Dias
Mariani, Odette
Delattre, Olivier
Bièche, Ivan
Servant, Nicolas
Rodrigues, Manuel
Pierga, Jean-Yves
Seban, Romain-David
Marangoni, Elisabetta
Morillon, Antonin
Théry, Clotilde
Proudhon, Charlotte
Piaggio, Eliane
Vallot, Céline
Mechta-Grigoriou, Fatima
Flavius, Julie
Dupain, Célia
Gentric, Géraldine
Vincent-Salomon, Anne
Kamal, Maud
Le Tourneau, Christophe
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-10-EQPX-03)
the Site de recherche intégré contre le cancer
Cancéropôle Ile-de-France
- License Information
-
More Information
Article History
Received: 10 November 2025
Accepted: 29 January 2026
First Online: 5 February 2026
Declarations
:
: All participants provided signed informed consent. All methods and study procedures were conducted in accordance with the Declaration of Helsinki, applicable French regulations governing biomedical research involving human participants, and the GDPR.SCANDARE was approved by a national research ethics committee (CPP Ile-de-France 3) and the French National Agency for the Safety of Medicines and Health Products (ANSM) on December 09th, 2016.
: Not applicable.
: Emanuela Romano: Bristol-Myers Squibb (BMS), AstraZeneca, Janssen-Cilag, Replimmune and Fonds Amgen France pour la Science et l’Humain. Manuel Rodrigues: AstraZeneca, GlaxoSmithKline, Immunocore, MSD, Johnson & Johnson/Janssen and Daiichi Sankyo/UCB Japan. Jean-Yves Pierga: Novartis, Daiichi Sankyo, Astra Zeneca, Gilead Sciences, Roche/Genentech, Pfizer, Roche/Genentech, MSD Oncology, Lilly, Seagen, Eisai Europe, Exact Sciences, Veracyte, Menarini Group and Servier. Maud Kamal: Roche and AstraZeneca. Christophe Le Tourneau: Roche, Seattle Genetics, Rakuten, Nanobiotix, MSD, BMS, Merck Serono, AstraZeneca, GlaxoSmithKline, Novartis, Celgene, Exscientia, ALX Oncology and Seattle Genetics. No other potential conflicts of interest were reported.
